Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next‐generation sequencing in lung adenocarcinoma ( LUAD )
Histopathology · 2026
DOI: 10.1111/his.70185 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Histopathology, 2026. Verfasst von Yingying Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, West China Hospital, Sichuan University, Chengdu, P.R. China. Hauptthemen laut MEDLINE: Lung Neoplasms, Tumor Suppressor Protein p53, Adenocarcinoma of Lung, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Sichuan Province, Youth Science Innovation Practice Station of the Digital Pathology Museum.
Abstract (Originalsprache)
Objectives TP53 mutations, prevalent in 50%–70% of lung adenocarcinoma (LUAD), are associated with poor prognosis and therapeutic resistance. This study aimed to evaluate the diagnostic accuracy of p53 immunohistochemistry (IHC) as a rapid and cost‐effective alternative to next‐generation sequencing (NGS) for TP53 mutation detection in LUAD patients. Materials and methods A multicentre cohort of 221 LUAD patients was analysed. TP53 mutation status was determined via NGS and compared with p53 IHC staining patterns. A multiparametric p53 IHC assessment system was established, integrating staining intensity, spatial distribution and subcellular localization data. Results p53 IHC demonstrated high concordance with TP53 mutation status, achieving an overall accuracy of 91.40% ( κ = 0.83). A novel ≥40% cut‐off for 3+ nuclear staining predicted TP53 mutations with 94.81% accuracy ( κ = 0.91). Complete p53 absence or cytoplasmic expression strongly correlated with truncating mutations (92.31% concordance), while missense mutations were linked to nuclear overexpression. TP53 ‐mutant tumours exhibited distinct molecular profiles, including increased frequencies of RB1 , MET , ERBB2 , MYC and PTCH1 mutations, alongside reduced STK11 comutations. Kaplan–Meier survival analysis demonstrated that p53 IHC serves as a reliable surrogate marker for TP53 mutation status, offering significant prognostic value in LUAD patients. Conclusion p53 IHC, particularly using a ≥40% cut‐off at 3+ intensity, is an accurate and accessible surrogate for TP53 mutation detection in LUAD patients. This method facilitates rapid molecular stratification, optimal resource utilization and informed prognostic and therapeutic decision‐making in routine pathology practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, P.R. China.
ORCID-Profile: Yingying Zhang, Ke Zheng, Yuan Tang, Ke Yang, Zihang Chen, Yuli Li, Yajing Zhang, Guiping Zhang, Li Qiu, Ran Peng, Xiaoyu Liu, Lili Jiang
Förderung
- Natural Science Foundation of Sichuan Province
- Youth Science Innovation Practice Station of the Digital Pathology Museum
Zitieren
APA
Zhang, Y., Zheng, K., Tang, Y., Yang, K., Chen, Z., Li, Y., Zhang, Y., Zhang, G., Qiu, L., Peng, R., Liu, X., & Jiang, L. (2026). Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next‐generation sequencing in lung adenocarcinoma ( LUAD ). Histopathology. https://doi.org/10.1111/his.70185
Vancouver
Zhang Y, Zheng K, Tang Y, Yang K, Chen Z, Li Y, et al. Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next‐generation sequencing in lung adenocarcinoma ( LUAD ). Histopathology. 2026. doi:10.1111/his.70185
BibTeX
@article{Zhang2026,
author = {Zhang, Yingying and Zheng, Ke and Tang, Yuan and Yang, Ke and Chen, Zihang and Li, Yuli and Zhang, Yajing and Zhang, Guiping and Qiu, Li and Peng, Ran and Liu, Xiaoyu and Jiang, Lili},
title = {Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next‐generation sequencing in lung adenocarcinoma ( LUAD )},
journal = {Histopathology},
year = {2026},
doi = {10.1111/his.70185}
}
EUVIMED